Abstract:Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat certain gastrointestinal disorders. It is fast emerging as an important target for the development of therapeutic engineered bacteria, benefiting from the wealth of knowledge of E. coli biology and ease of manipulation. Bacterial synthetic biology projects commonly utilize engineered plasmid vectors, which are simple to engineer and can reliably achieve high levels of protein expression. However, plasmids typically require antibiotics for maintenance, and the administration of an antibiotic is often incompatible with in vivo experimentation or treatment. EcN natively contains plasmids pMUT1 and pMUT2, which have no known function but are stable within the bacteria. Here, we describe the development of the pMUT plasmids into a robust platform for engineering EcN for in vivo experimentation, alongside a CRISPR-Cas9 system to remove the native plasmids. We systematically engineered both pMUT plasmids to contain selection markers, fluorescent markers, temperature sensitive expression, and curli secretion systems to export a customizable functional material into the extracellular space. We then demonstrate that the engineered plasmids were maintained in bacteria as the engineered bacteria pass through the mouse GI tract without selection, and that the secretion system remains functional, exporting functionalized curli proteins into the gut. Our plasmid system presents a platform for the rapid development of therapeutic EcN bacteria.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acssynbio.0c00466?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acssynbio.0c00466</a>.Table S1: DNA primers used in this work; Table S2: Sequence of UNS sequences; Table S3: gRNA sequences used in the pFREE and pCryptDel plasmids; Table S4: Variant TlpA* promoter sequences, and their properties; Figure S1: Detailed plasmid maps of pMUT1 and pMUT2; Figure S2: GFP and RFP characterization of engineered pMUT plasmids; Figure S3: Plasmid vectors to cure EcN cryptic plasmids; Figure S4: Curing native pMUT plasmids; Figure S5: In vivo synthetic plasmid loss; Supplementary methods for Figure S5; Figure S6: In vitro growth characterization of bacteria used in vivo (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_001.pdf">PDF</a>)Dataset S1: All data used in the figures (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_002.xlsx">XLSX</a>)Dataset S2: In vivo data (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_003.xlsx">XLSX</a>)This article has not yet been cited by other publications.

The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers

Conquering homocystinuria with engineered probiotics

Bioengineering of Escherichia coli Nissle 1917 for Production and Excretion of Spermidine, a Key Metabolite in Human Health

Heterologous Biosynthesis of Methanobactin from Methylocystis sp. Strain SB2 in Methylosinus trichosporium OB3b

Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster

Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis

Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model

Doping In Vivo Alkylation in E. coli by Introducing the Direct Sulfurylation Pathway of S. cerevisiae

Controlled colonization of the human gut with a genetically engineered microbial medicine

Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia

Bio-engineering a common probiotic to exploit colonic inflammation promotes reliable efficacy in translational models of colitis

Treatment of Hyperammonemia by Transplanting a Symbiotic Pair of Intestinal Microbes

One-step biosynthesis of α-keto-γ-methylthiobutyric acid from L-methionine by an Escherichia coli whole-cell biocatalyst expressing an engineered L-amino acid deaminase from Proteus vulgaris

Assessment of Potential Anti-Methanogenic and Antimicrobial Activity of Ethyl Nitroacetate, α-Lipoic Acid, Taurine and L-Cysteinesulfinic Acid In Vitro

Intracellular Gelation-Mediated Living Bacteria for Advanced Biotherapeutics in Mouse Models

Development of a Limosilactobacillus reuteri therapeutic delivery platform with reduced colonization potential

Engineered Bacillus subtilis as oral probiotics to enhance clearance of blood lactate

Plasmid Vectors for in Vivo Selection-Free Use with the Probiotic E. coli Nissle 1917

In situ deposition of nanobodies by an engineered commensal microbe promotes survival in a mouse model of enterohemorrhagic E. coli

Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria

Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors